Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Receivables for 15 consecutive years, with $707.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 43.32% year-over-year to $707.3 million, compared with a TTM value of $707.3 million through Dec 2025, up 43.32%, and an annual FY2025 reading of $707.3 million, up 43.32% over the prior year.
  • Receivables was $707.3 million for Q4 2025 at Neurocrine Biosciences, down from $728.0 million in the prior quarter.
  • Across five years, Receivables topped out at $728.0 million in Q3 2025 and bottomed at $151.0 million in Q1 2021.
  • Average Receivables over 4 years is $439.8 million, with a median of $463.3 million recorded in 2024.
  • The sharpest move saw Receivables fell 1.5% in 2021, then skyrocketed 51.32% in 2025.
  • Year by year, Receivables stood at $166.6 million in 2021, then skyrocketed by 170.41% to $450.5 million in 2023, then grew by 9.54% to $493.5 million in 2024, then soared by 43.32% to $707.3 million in 2025.
  • Business Quant data shows Receivables for NBIX at $707.3 million in Q4 2025, $728.0 million in Q3 2025, and $595.7 million in Q2 2025.